INC.

BIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023

by

Educational and Training Programs Introducing Broader Community of Dentists to Experience Industry-Leading Dental Lasers for the First Time LAKE FOREST, Calif., May 11, 2023 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the first quarter ended March 31, 2023. First Quarter Financial Highlights Reported revenue of … Read more

Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023

by

CRANBURY, N.J., May 11, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 16, … Read more

Thorne HealthTech Reports First Quarter 2023 Results

by

Net Sales Growth of 20.7%; Reaffirms Full-Year 2023 Guidance NEW YORK, May 11, 2023 /PRNewswire/ — Thorne HealthTech, Inc. (“Thorne HealthTech”, “Thorne” or the “Company”) (NASDAQ: THRN), a leader in delivering personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the first quarter ended March 31, 2023. First Quarter … Read more

Invivoscribe oznamuje schválenie testu mutácie LeukoStrat CDx FLT3 podľa nariadenia IVDR

by

SAN DIEGO, 11. mája 2023 /PRNewswire/ — „Dnes s potešením oznamujeme, že test mutácie LeukoStrat® CDx FLT3 spoločnosti Invivoscribe schválila organizácia BSI (Holandsko) a agentúra EMA ako test CDx triedy C, ktorý spĺňa nové prísne požiadavky nariadenia o diagnostických zdravotníckych pomôckach in vitro [nariadenie (EÚ) 2017/746] (ďalej len IVDR). Invivoscribe je jednou z prvých spoločností na … Read more

Invivoscribe ogłasza uzyskanie zatwierdzenia testu CDx mutacji genu FLT3 LeukoStrat zgodnie z rozporządzeniem IVDR

by

SAN DIEGO, 11 maja 2023 r. /PRNewswire/ — „Mamy dzisiaj przyjemność ogłosić, że test CDx mutacji genu FLT3 LeukoStrat® spółki Invivoscribe uzyskał zatwierdzenie BSI (Holandia) i EMA jako test CDx klasy C po spełnieniu ścisłych nowych wymogów Rozporządzenia w sprawie wyrobów medycznych do diagnostyki in vitro (IVDR) (Rozporządzenia (UE) 2017/746). Invivoscribe jest jedną z pierwszych … Read more

Система анализа мутаций LeukoStrat CDx FLT3 от компании Invivoscribe были одобрены IVDR

by

САН-ДИЕГО, 11 мая 2023 г. /PRNewswire/ — «Сегодня мы с радостью объявляем о том, что разработанная компанией Invivoscribe тест-система мутаций LeukoStrat® CDx FLT3 была одобрена BSI (Нидерланды) и EMA в качестве тест-системы класса C CDx, отвечающей новым строгим требованиям IVDR (Регламент (ЕС) 2017/746). Invivoscribe – одна из первых в мире компаний, получивших одобрение IVDR на … Read more

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

by

Update on FDA Meeting Outcome Expected Next Month PRINCETON, N.J., May 11, 2023 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States (U.S.) Food and Drug Administration … Read more

Moleculin Reports First Quarter 2023 Financial Results

by

– Continued clinical and operational execution across ongoing development programs with growing body of positive preclinical and clinical data – Sufficient capital to fund operations into the third quarter of 2024 – Company to host conference call and webcast today at 8:30 AM ET HOUSTON, May 11, 2023 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” … Read more

Les résultats positifs de premier ordre de l’essai de phase 2 montrent que le candidat-vaccin combiné COVID-Influenza de Novavax, le candidat-vaccin autonome contre la grippe et les candidats-vaccins à forte dose contre la COVID-19 présentent de solides réponses immunitaires USA – Français India – English USA – Deutsch USA – English Brazil – Português Latin America – español USA – español

by

Cet essai de phase 2 évalue trois candidats-vaccins : Candidat-vaccin combiné COVID-Influenza, candidat-vaccin autonome contre la grippe et candidat-vaccin à forte dose contre la COVID-19 Les réponses immunitaires initiales de premier ordre des trois candidats-vaccins étaient robustes par rapport aux comparateurs autorisés Pour le candidat-vaccin antigrippal autonome, les réponses de l’IH étaient de 31 à 56 % … Read more

Nippon Express Italia Obtains IATA CEIV Pharma Certification for Its Facility near Milan Malpensa Airport

by

TOKYO, May 11, 2023 /PRNewswire/ — Nippon Express Italia S.p.A. (hereinafter “NX Italia”), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association (IATA), for its warehouse facility in Lainate, near Milan Malpensa Airport, effective April 3 of this year. Logo: https://kyodonewsprwire.jp/img/202305095498-O1-I17xe4r6 Photos … Read more